Latest news and press releases about Jasper Therapeutics, Inc. (JSPR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
Price
| Price | $0.58 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 11.94 |
| EV / EBITDA | -0.14 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -618.87% |
| Return on Invested Capital | -1305.04% |
| Return on Assets | -269.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLD · BTAI · CELU · GBIO · MURA · NXTC · PSTV
Explore sector: Healthcare · Biotechnology
More sections of JSPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks